Christopher Missling Email Address

President

Anavex is a biopharmaceutical company developing drugs for the treatment of cancer and neurological diseases.

• Educated at the University of British Columbia, the University of Toronto, Harvard Medical School and the London School of Economics; • Studied mathematics and chemistry as an undergraduate; • Earned post-doctoral specialist certifications in three disciplines; • Formerly a Professor at the David Geffen School of Medicine at the University of California, Los Angeles and Director of several major multidisciplinary clinical programs — pioneered new techniques in partial and live-donor liver transplantation; • Co-founded the British Columbia liver transplant program as well as the first national organ sharing program in Canada; • A basic science and clinical investigator with more than 190 publications in peer-reviewed journals in the fields of ischemic injury, immunology, immunopharmacology, transplantation, and liver disease; • Studied corporate finance, financial markets, and derivatives at the London School of Economics; • Combination of skills in medical research and finance affords a unique ability to undertake in-depth analysis and financial modeling of healthcare-related businesses and investment opportunities; • Deep domain knowledge of the life sciences, clinical trial methodology, and regulatory landscape for Canada, the US, and the European Union; • Facility with both parametric and non-parametric statistical methods, and relational database management systems; • Rolodex includes contacts with leading securities lawyers and healthcare specialist investment bankers; • Served as a corporate advisor, a "C" level executive, and board member with a number of firms; • Focused on creating shareholder value and generating returns commensurate with the risk.